Clinical trials

Since POETIC's inception, two first-in-child clinical trials have been conducted increasing early access to novel molecularly targeted agents for treatment of children and adolescents with refractory malignancies after completion of adult Phase I studies. One of the studies resulted in evidence of clinical benefit in patients with tumors of the central nervous system using a novel agent targeting the epidermal growth factor receptor, cetuximab. These findings have provided the scientific rationale for a Phase II study targeting high grade central nervous system tumors, which is on-going.

Active clinical trials

Closed to accrual

Completed studies

  • Phase I trial of Cabazitaxel in patients with solid tumors including CNS
  • Phase I trial of Cabazitaxel in patients with solid tumors including CNS
  • Phase I trial of 17-AAG in patients with solid tumors and leukemia
  • Phase I trial of Cetuximab and Irinotecan in patients with solid tumors including CNS
  • Phase I trial of Oxaliplatin, Fluorouracil, and Leucovorin  in patients with solid tumors
  • Phase I trial of Clofarabine and Cyclophosphamide  in patients with leukemia
  • Phase I trial of Ridaforolimus  in patients with solid tumors
  • Safety and pharmacokinetics of Atezolisumb (MPDL3280A) in pediatric and young adults patients with previously treated solid tumors

Programs

Return to Top

Join our mailing list

Receive updates on POETIC new projects and programs.

* indicates required

 Pediatric Oncology Experimental Therapeutics Investigators' Consortium

© Copyright 2021   |   Website designed by Amanda M. Buckley

Connect

toll-free
(650) 736-0269

email
poeticdcc@stanford.edu